EXCEL Clinical Trial

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 30 days

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 6 months

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 1 year

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 2 years

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 3 years

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 4 years

Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 5 years

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 30 days

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 6 months

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 1 year

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).

Time frame: 0 to 2 years

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

Death: * Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). * Non-cardiac death is defined as a death not due to cardiac causes (as defined above). Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.

Time frame: 0 to 3 years

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

Death: * Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). * Non-cardiac death is defined as a death not due to cardiac causes (as defined above). Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.

Time frame: 0 to 4 years

Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia

Death: * Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). * Non-cardiac death is defined as a death not due to cardiac causes (as defined above). Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.

Time frame: 0 to 5 years

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 30 days

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 6 months

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 1 year

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 2 years

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 3 years

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 4 years

Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)

All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Time frame: 0 to 5 years

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: In-hospital (≤ 7 days of post index procedure)

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 30 days

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 6 months

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 1 year

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 2 years

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 3 years

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 4 years

Number of Participants With Protocol Defined MI

Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.

Time frame: 0 to 5 years

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 30 days

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 6 months

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 1 year

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 2 years

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 3 years

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 4 years

Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)

Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,\* and primary subarachnoid hemorrhage. * All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.

Time frame: 0 to 5 years

Number of Participants With Disability Following Stroke Event

In case of an event of stroke disability at 90-days±2 weeks will be an overall measurement of severity of stroke as assessed by modified Rankin Scale (mRS) scale. Stroke disability will be classified using an adaptation of the modified Rankin Scale as follows, the assessment of which will be based on the Modified Rankin Disability Questionnaire. Scale 0; No stroke symptoms at all. (May have other complaints) Scale 1; No significant disability; symptoms present but no physical or other limitations. Scale 2; Slight disability; limitations in participation in usual social roles, but independent for activities of daily living (ADL) Scale 3; Some need for assistance but able to walk without assistance Scale 4; Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care Scale 5; Severe disability; requiring constant nursing care and attention.

Time frame: 90 days ± 2 weeks

Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 30 days

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 6 months

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 1 year

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 2 years

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 3 years

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 4 years

Number of Participants With Ischemia Driven Revascularizations

A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; or * Ischemic ECG changes at rest in a distribution consistent with the target vessel; or * Typical ischemic symptoms referable to the target lesion; or * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; or * Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80

Time frame: 0 to 5 years

Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 30 days

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 6 months

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 1 year

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 2 years

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 3 years

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 4 years

Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: * A positive functional study corresponding to the area served by the target lesion; * Ischemic ECG changes at rest in a distribution consistent with the target vessel; * Typical ischemic symptoms referable to the target lesion; * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the * plaque burden must also be ≥ 60%; * FFR of the target lesion ≤ 0.80 * A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.

Time frame: 0 to 5 years

Percentage of Participants With Major Adverse Events (MAE)

Composite of death, myocardial infarction, stroke, transfusion of ≥ 2 units of blood, major arrhythmia, unplanned coronary revascularization for ischemia, any unplanned surgery or radiologic procedure, renal failure, sternal wound dehiscence, infection requiring antibiotics for treatment, intubation for \> 48 hours, or post-pericardiotomy syndrome.

Time frame: In-hospital

Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable

Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis. Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent\&presence of at least 1 of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive thrombus * Occlusive thrombus. Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. Probable stent thrombosis may occur after intracoronary stenting due to: * Unexplained death within first 30 days * Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis\&in the absence of any other obvious cause.

Time frame: Early (0-30 days)

Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable

Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis. Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent\&presence of at least 1 of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive thrombus * Occlusive thrombus. Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. Probable stent thrombosis may occur after intracoronary stenting due to: * Unexplained death within first 30 days * Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis\&in the absence of any other obvious cause.

Time frame: Acute (<= 24 hours)

Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable

Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis. Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent\&presence of at least 1 of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive thrombus * Occlusive thrombus. Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. Probable stent thrombosis may occur after intracoronary stenting due to: * Unexplained death within first 30 days * Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis\&in the absence of any other obvious cause.

Time frame: Subacute (1-30 days)

Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable

Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis. Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent\&presence of at least 1 of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive thrombus * Occlusive thrombus. Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. Probable stent thrombosis may occur after intracoronary stenting due to: * Unexplained death within first 30 days * Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis\&in the absence of any other obvious cause.

Time frame: Late (>30 days - 1 year)

Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable

Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis. Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent\&presence of at least 1 of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive thrombus * Occlusive thrombus. Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. Probable stent thrombosis may occur after intracoronary stenting due to: * Unexplained death within first 30 days * Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis\&in the absence of any other obvious cause.

Time frame: Very late (>1 year)

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: In-hospital (≤ 7 days of index-procedure)

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 30 days

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 6 months

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 1 year

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 2 years

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 3 years

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 4 years

Number of Participants With Graft Stenosis or Occlusion

Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 0 to 5 years

Number of Participants With Requirement for Blood Product Transfusion

All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: * Δ Hemoglobin = \[baseline Hgb - post-transfusion Hgb\] + \[number of transfused units\]; * Δ Hematocrit = \[baseline Hct - post-transfusion Hct\] + \[number of transfused units X 3\].

Time frame: 30 days

Number of Participants With Requirement for Blood Product Transfusion

All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: * Δ Hemoglobin = \[baseline Hgb - post-transfusion Hgb\] + \[number of transfused units\]; * Δ Hematocrit = \[baseline Hct - post-transfusion Hct\] + \[number of transfused units X 3\].

Time frame: 3 years

Number of Participants With Requirement for Blood Product Transfusion

All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: * Δ Hemoglobin = \[baseline Hgb - post-transfusion Hgb\] + \[number of transfused units\]; * Δ Hematocrit = \[baseline Hct - post-transfusion Hct\] + \[number of transfused units X 3\].

Time frame: 4 years

Number of Participants With Requirement for Blood Product Transfusion

All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: * Δ Hemoglobin = \[baseline Hgb - post-transfusion Hgb\] + \[number of transfused units\]; * Δ Hematocrit = \[baseline Hct - post-transfusion Hct\] + \[number of transfused units X 3\].

Time frame: 5 years

Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding

Bleeding will be classified by the TIMI hemorrhage classification Severity: Major: * Intracranial hemorrhage * A ≥5 g/dL decrease in the hemoglobin concentration * A ≥15% absolute decrease in the hematocrit Minor: * Observed blood loss: * A ≥ 3 g/dL decrease in the hemoglobin concentration * A ≥ 10% absolute decrease in the hematocrit * No observed blood loss: * A ≥ 4 g/dL decrease in the hemoglobin concentration * A ≥ 12% absolute decrease in the hematocrit Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a \< 3 g/dL decrease in hemoglobin concentration or \< 9% decrease in the hematocrit.

Time frame: 30 days

Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding

Bleeding will be classified by the TIMI hemorrhage classification Severity: Major: * Intracranial hemorrhage * A ≥5 g/dL decrease in the hemoglobin concentration * A ≥15% absolute decrease in the hematocrit Minor: * Observed blood loss: * A ≥ 3 g/dL decrease in the hemoglobin concentration * A ≥ 10% absolute decrease in the hematocrit * No observed blood loss: * A ≥ 4 g/dL decrease in the hemoglobin concentration * A ≥ 12% absolute decrease in the hematocrit Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a \< 3 g/dL decrease in hemoglobin concentration or \< 9% decrease in the hematocrit.

Time frame: 3 years

Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding

Bleeding will be classified by the TIMI hemorrhage classification Severity: Major: * Intracranial hemorrhage * A ≥5 g/dL decrease in the hemoglobin concentration * A ≥15% absolute decrease in the hematocrit Minor: * Observed blood loss: * A ≥ 3 g/dL decrease in the hemoglobin concentration * A ≥ 10% absolute decrease in the hematocrit * No observed blood loss: * A ≥ 4 g/dL decrease in the hemoglobin concentration * A ≥ 12% absolute decrease in the hematocrit Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a \< 3 g/dL decrease in hemoglobin concentration or \< 9% decrease in the hematocrit.

Time frame: 4 years

Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding

Bleeding will be classified by the TIMI hemorrhage classification Severity: Major: * Intracranial hemorrhage * A ≥5 g/dL decrease in the hemoglobin concentration * A ≥15% absolute decrease in the hematocrit Minor: * Observed blood loss: * A ≥ 3 g/dL decrease in the hemoglobin concentration * A ≥ 10% absolute decrease in the hematocrit * No observed blood loss: * A ≥ 4 g/dL decrease in the hemoglobin concentration * A ≥ 12% absolute decrease in the hematocrit Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a \< 3 g/dL decrease in hemoglobin concentration or \< 9% decrease in the hematocrit.

Time frame: 5 years

Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding

Type 0: No bleeding Type 1: Bleeding that is not actionable\&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: Any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation. Type 3 Type 3a * Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL * Any transfusion with overt bleeding Type 3b * Overt bleeding plus hemoglobin drop ≥5 g/dL\* * Cardiac tamponade * Bleeding requiring surgical intervention for control * Bleeding requiring intravenous vasoactive agents Type 3c * Intracranial hemorrhage * Subcategories confirmed by autopsy or imaging or lumbar puncture * Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: Fatal bleeding

Time frame: 30 days

Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding

Type 0: no bleeding Type 1: bleeding that is not actionable\&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation. Type 3 Type 3a * Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL * Any transfusion with overt bleeding Type 3b * Overt bleeding plus hemoglobin drop ≥5 g/dL\* * Cardiac tamponade * Bleeding requiring surgical intervention for control * Bleeding requiring intravenous vasoactive agents Type 3c * Intracranial hemorrhage * Subcategories confirmed by autopsy or imaging or lumbar puncture * Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding

Time frame: 3 years

Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding

Type 0: no bleeding Type 1: bleeding that is not actionable\&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation. Type 3 Type 3a * Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL * Any transfusion with overt bleeding Type 3b * Overt bleeding plus hemoglobin drop ≥5 g/dL\* * Cardiac tamponade * Bleeding requiring surgical intervention for control * Bleeding requiring intravenous vasoactive agents Type 3c * Intracranial hemorrhage * Subcategories confirmed by autopsy or imaging or lumbar puncture * Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding

Time frame: 4 years

Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding

Type 0: no bleeding Type 1: bleeding that is not actionable\&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation. Type 3 Type 3a * Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL * Any transfusion with overt bleeding Type 3b * Overt bleeding plus hemoglobin drop ≥5 g/dL\* * Cardiac tamponade * Bleeding requiring surgical intervention for control * Bleeding requiring intravenous vasoactive agents Type 3c * Intracranial hemorrhage * Subcategories confirmed by autopsy or imaging or lumbar puncture * Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding

Time frame: 5 years

Number of Participants With Major Adverse Events (MAE)

* death * myocardial infarction * stroke * Transfusion of ≥2 units of blood * TIMI major or minor bleeding * major arrhythmia * unplanned coronary revascularization for ischemia * any unplanned surgery or therapeutic radiologic procedure * renal failure * sternal wound dehiscence * infection requiring antibiotics for treatment * intubation for \> 48 hours * post-pericardiotomy syndrome

Time frame: 30 days

Number of Participants With Complete Revascularization (Residual = 0)

1. Complete anatomic revascularization requires revascularization of all vessels ≥2.0 mm reference vessel diameter with a DS ≥60% (both as measured by core angiographic laboratory analysis). -While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. ≥2.5 mm vessels, DS ≥70%, etc.) 2. From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization. 3. Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS \<50% considered successfully revascularized). 4. Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.

Time frame: At Baseline

Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: In-hospital (≤ 7 days of post index procedure)

Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 1 year

Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 2 years

Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 3 years

Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 4 years

Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion

\- Definite ST occurred by either angiographic/pathologic confirmation of ST. Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent\&presence of at least 1 of the following criteria within 48-hours: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes * Typical rise\&fall in cardiac biomarkers * Non-occlusive \&occlusive thrombus Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy. -Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.

Time frame: 5 years